A 16-week randomized, double-blind, parallel-group, multicenter, placebo- and active- (metformin) controlled study to evaluate the effect on whole body insulin sensitivity of tesaglitazar therapy when administered to patients with type 2 diabetes
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Tesaglitazar (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms ARAMIS
- Sponsors AstraZeneca
- 12 Dec 2007 Status changed from in progress to completed.
- 08 Aug 2006 Status change
- 29 Mar 2006 New trial record.